Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

855 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT.
Spyridonidis A, Labopin M, Schmid C, Volin L, Yakoub-Agha I, Stadler M, Milpied N, Socie G, Browne P, Lenhoff S, Sanz MA, Aljurf M, Mohty M, Rocha V; Immunotherapy Subcommittee of Acute Leukemia Working Party. Spyridonidis A, et al. Among authors: stadler m. Leukemia. 2012 Jun;26(6):1211-7. doi: 10.1038/leu.2011.351. Epub 2012 Jan 31. Leukemia. 2012. PMID: 22290066
Quantitative MRD monitoring identifies distinct GVL response patterns after allogeneic stem cell transplantation for chronic lymphocytic leukemia: results from the GCLLSG CLL3X trial.
Ritgen M, Böttcher S, Stilgenbauer S, Bunjes D, Schubert J, Cohen S, Humpe A, Hallek M, Kneba M, Schmitz N, Döhner H, Dreger P; German CLL Study Group. Ritgen M, et al. Leukemia. 2008 Jul;22(7):1377-86. doi: 10.1038/leu.2008.96. Epub 2008 Apr 17. Leukemia. 2008. PMID: 18418404 Clinical Trial.
Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR-ABL1-positive acute lymphoblastic leukemia.
Pfeifer H, Wassmann B, Bethge W, Dengler J, Bornhäuser M, Stadler M, Beelen D, Vucinic V, Burmeister T, Stelljes M, Faul C, Dreger P, Kiani A, Schäfer-Eckart K, Schwerdtfeger R, Lange E, Kubuschok B, Horst HA, Gramatzki M, Brück P, Serve H, Hoelzer D, Gökbuget N, Ottmann OG; GMALL Study Group. Pfeifer H, et al. Among authors: stadler m. Leukemia. 2013 Jun;27(6):1254-62. doi: 10.1038/leu.2012.352. Epub 2012 Dec 5. Leukemia. 2013. PMID: 23212150 Clinical Trial.
Proteomic peptide profiling for preemptive diagnosis of acute graft-versus-host disease after allogeneic stem cell transplantation.
Weissinger EM, Metzger J, Dobbelstein C, Wolff D, Schleuning M, Kuzmina Z, Greinix H, Dickinson AM, Mullen W, Kreipe H, Hamwi I, Morgan M, Krons A, Tchebotarenko I, Ihlenburg-Schwarz D, Dammann E, Collin M, Ehrlich S, Diedrich H, Stadler M, Eder M, Holler E, Mischak H, Krauter J, Ganser A. Weissinger EM, et al. Among authors: stadler m. Leukemia. 2014 Apr;28(4):842-52. doi: 10.1038/leu.2013.210. Epub 2013 Jul 11. Leukemia. 2014. PMID: 23842427 Free PMC article.
Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation.
Panagiota V, Thol F, Markus B, Fehse B, Alchalby H, Badbaran A, Lehmann U, Koenecke C, Shahswar R, Chaturvedi A, Stadler M, Eder M, Göhring G, Koenigsmann M, Kloos A, Trummer A, Schroeder T, Kobbe G, Thiede C, Platzbecker U, Schlegelberger B, Kreipe HH, Ganser A, Kröger N, Heuser M. Panagiota V, et al. Among authors: stadler m. Leukemia. 2014 Jul;28(7):1552-5. doi: 10.1038/leu.2014.66. Epub 2014 Feb 7. Leukemia. 2014. PMID: 24504025 No abstract available.
Low frequency of calreticulin mutations in MDS patients.
Heuser M, Panagiota V, Koenecke C, Fehse B, Alchalby H, Badbaran A, Shahswar R, Stadler M, Eder M, Göhring G, Trummer A, Schroeder T, Kobbe G, Thiede C, Platzbecker U, Schlegelberger B, Kroeger N, Ganser A, Thol F. Heuser M, et al. Among authors: stadler m. Leukemia. 2014 Sep;28(9):1933-4. doi: 10.1038/leu.2014.165. Epub 2014 May 21. Leukemia. 2014. PMID: 24850292 No abstract available.
The proteome pattern cGvHD_MS14 allows early and accurate prediction of chronic GvHD after allogeneic stem cell transplantation.
Weissinger EM, Human C, Metzger J, Hambach L, Wolf D, Greinix HT, Dickinson AM, Mullen W, Jonigk D, Kuzmina Z, Kreipe H, Schweier P, Böhm O, Türüchanow I, Ihlenburg-Schwarz D, Raad J, Durban A, Schiemann M, Könecke C, Diedrich H, Holler E, Beutel G, Krauter J, Ganser A, Stadler M. Weissinger EM, et al. Among authors: stadler m. Leukemia. 2017 Mar;31(3):654-662. doi: 10.1038/leu.2016.259. Epub 2016 Sep 28. Leukemia. 2017. PMID: 27677743
Risk of sinusoidal obstruction syndrome in allogeneic stem cell transplantation after prior gemtuzumab ozogamicin treatment: a retrospective study from the Acute Leukemia Working Party of the EBMT.
Battipaglia G, Labopin M, Candoni A, Fanin R, El Cheikh J, Blaise D, Michallet M, Ruggeri A, Contentin N, Ribera JM, Stadler M, Sierra J, von dem Borne PA, Bloor A, Socié G, Nagler A, Mohty M. Battipaglia G, et al. Among authors: stadler m. Bone Marrow Transplant. 2017 Apr;52(4):592-599. doi: 10.1038/bmt.2016.302. Epub 2017 Jan 16. Bone Marrow Transplant. 2017. PMID: 28092357
855 results